Eli Lilly agreed to acquire Ventyx Biosciences for $1.2 billion in cash, offering $14 per share, a roughly 62% premium to Ventyx’s 30-day volume-weighted average price as of January 5.1345
The Ventyx acquisition is aimed at expanding Lilly’s inflammatory and immunology pipeline, particularly with oral small-molecule drugs targeting chronic inflammatory and immune-mediated diseases.1345
A central strategic rationale is access to NLRP3 inhibitors, a drug class Lilly did not previously have, which target inflammation implicated in neuroinflammatory, cardiometabolic, cardiovascular and other immunological diseases.2345
Key Ventyx assets Lilly is acquiring include:
- *VTX3232:*
an oral NLRP3 inhibitor with Phase 2 data showing biomarker reductions and signals of benefit in Parkinson’s symptoms and cardiometabolic risk, including in patients on GLP‑1 therapy.25
- *VTX2735:*
a peripherally restricted NLRP3 inhibitor in development for recurrent pericarditis.14
- *Tamuzimod (VTX002):*
an S1P1 receptor modulator that has completed Phase II for ulcerative colitis.14
- *VTX958:*
an oral allosteric TYK2 inhibitor in Phase II for Crohn’s disease.14
The deal is expected to close in the first half of 2026, subject to Ventyx stockholder approval and customary regulatory clearances; it is not subject to any financing condition.34
Lilly frames the acquisition as part of a broader strategy to diversify beyond its obesity blockbusters (Zepbound and Mounjaro) and to strengthen its presence in cardiometabolic health, neurodegeneration and autoimmunity.145
Analysts note the transaction underscores big pharma interest in the NLRP3 inhibitor class, with potential read-across for other companies working on NLRP3 such as Neumora, Neurocrine and BioAge.14
In parallel with the Ventyx buy, Lilly also signed a separate cancer-focused collaboration with InduPro, aimed at expanding its oncology pipeline (cancer pact referenced in coverage as part of Lilly’s broader pipeline build; specific financial terms and programs are distinct from the $1.2B Ventyx deal).4
Lilly executives state that Ventyx’s portfolio will support the company’s push for innovative oral therapies as alternatives or complements to injectable biologics in immune-mediated and cardiometabolic diseases.135
The acquisition continues Lilly’s pattern of bolt-on biotech deals to strengthen key therapeutic areas, following earlier transactions such as Loxo Oncology and Dice Therapeutics, and complements its separate high-value research and license agreement with Nimbus Therapeutics in obesity.15
Sources:
1. https://www.pharmaceutical-technology.com/news/eli-lilly-acquires-inflammatory-specialist-ventyx-for-1-2bn/
2. https://www.fiercebiotech.com/biotech/lilly-buys-inflammation-biotech-venytx-12b-wake-parkinsons-cardiovascular-readouts
3. https://www.prnewswire.com/news-releases/lilly-to-acquire-ventyx-biosciences-to-advance-oral-therapies-targeting-inflammatory-mediated-diseases-302655657.html
4. https://www.biospace.com/deals/lilly-bulks-up-inflammatory-pipeline-with-1-2b-ventyx-buy-indupro-cancer-pact
5. https://www.biopharmadive.com/news/lilly-ventyx-acquire-deal-nlrp3-inflammasome/808988/